ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study: Safety, Toxicity and Immunological Effects of Peritumorally Delivered Immunotherapy in Early-stage Cervical Cancer
Latest Information Update: 26 Oct 2023
At a glance
- Drugs Balstilimab (Primary) ; Botensilimab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- Acronyms ITHACA Study
Most Recent Events
- 26 Oct 2023 New trial record